A detailed history of Shilanski & Associates, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Shilanski & Associates, Inc. holds 900 shares of AMGN stock, worth $287,622. This represents 0.09% of its overall portfolio holdings.

Number of Shares
900
Previous 904 0.44%
Holding current value
$287,622
Previous $257,000 9.34%
% of portfolio
0.09%
Previous 0.09%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 18, 2024

SELL
$262.75 - $319.31 $1,051 - $1,277
-4 Reduced 0.44%
900 $281,000
Q1 2024

Apr 10, 2024

SELL
$268.87 - $324.56 $47,321 - $57,122
-176 Reduced 16.3%
904 $257,000
Q4 2023

Jan 09, 2024

SELL
$255.7 - $288.46 $15,342 - $17,307
-60 Reduced 5.26%
1,080 $311,000
Q3 2023

Nov 13, 2023

BUY
$218.65 - $271.46 $218 - $271
1 Added 0.09%
1,140 $306,000
Q2 2023

Jul 28, 2023

SELL
$214.27 - $253.37 $9,213 - $10,894
-43 Reduced 3.64%
1,139 $252,000
Q1 2023

May 11, 2023

BUY
$225.79 - $275.2 $1,580 - $1,926
7 Added 0.6%
1,182 $285,000
Q4 2022

Jan 30, 2023

SELL
$229.03 - $291.01 $183,682 - $233,390
-802 Reduced 40.57%
1,175 $308,000
Q3 2022

Nov 03, 2022

BUY
$224.46 - $253.15 $112,230 - $126,575
500 Added 33.85%
1,977 $446,000
Q2 2022

Aug 02, 2022

SELL
$230.71 - $256.74 $14,996 - $16,688
-65 Reduced 4.22%
1,477 $359,000
Q1 2022

Apr 20, 2022

SELL
$219.27 - $242.57 $23,461 - $25,954
-107 Reduced 6.49%
1,542 $373,000
Q4 2021

Jan 12, 2022

SELL
$198.88 - $227.6 $15,313 - $17,525
-77 Reduced 4.46%
1,649 $371,000
Q3 2021

Oct 12, 2021

BUY
$212.27 - $248.7 $36,085 - $42,279
170 Added 10.93%
1,726 $367,000
Q2 2021

Aug 13, 2021

SELL
$233.58 - $259.14 $1,635 - $1,813
-7 Reduced 0.45%
1,556 $379,000
Q1 2021

Apr 14, 2021

BUY
$221.91 - $258.6 $346,845 - $404,191
1,563 New
1,563 $389,000

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Shilanski & Associates, Inc. Portfolio

Follow Shilanski & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shilanski & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Shilanski & Associates, Inc. with notifications on news.